Physician profile
Anthony Antonello
NPI 1548265374
$3,838.25
in general payments reported to CMS, 2019-2025
30 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $381 · 2021: $920 · 2022: $569 · 2023: $428 · 2024: $660 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,558.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $633.53 | 2019-2025 | Eylea Hd, Eylea |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $294.19 | 2019-2021 | |
| Alcon Vision LLC | $293.42 | 2019-2025 | Clareon, Tryptyr, Rocklatan |
| Sun Pharmaceutical Industries INC. | $267.95 | 2019-2025 | Cequa |
| Notal Vision, INC. | $242.40 | 2021 | |
| Bausch & Lomb Americas INC. | $208.10 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Mallinckrodt Hospital Products INC. | $206.68 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $191.05 | 2019-2021 | |
| Harrow Eye, LLC | $169.96 | 2024-2025 | Vevye, Iheezo |
| Allergan, INC. | $162.23 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $157.49 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $121.33 | 2024-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $119.74 | 2019-2023 | |
| Amgen INC. | $111.63 | 2024-2025 | Tepezza |
| Abbvie INC. | $101.50 | 2022-2023 | Vuity, Lumigan, Alphagan P |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $81.84 | 2024 | Izervay |
| Horizon Therapeutics Plc | $81.81 | 2021-2023 | Tepezza |
| Oyster Point Pharma, INC. | $80.61 | 2022-2024 | Tyrvaya |
| Apellis Pharmaceuticals, INC. | $55.81 | 2024 | Syfovre |
| Kala Pharmaceuticals, INC. | $45.32 | 2021 | |
| Abb Con-Cise Optical Group LLC | $28.67 | 2024 | Spectacle Lenses, Contact Lens |
| Carl Zeiss Meditec, INC. | $25.96 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $24.79 | 2023 | Acuvue |
| Alexion Pharmaceuticals, INC. | $23.96 | 2023 | Soliris |
| Rayner Intraocular Lenses Limited | $22.23 | 2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Biotissue Holdings INC. | $19.57 | 2019 | |
| Ani Pharmaceuticals, INC. | $18.66 | 2024 | Purified Cortrophin Gel |
| Katena Products, INC. (Dba Corza Medical) | $17.17 | 2019 | |
| Eyevance Pharmaceuticals LLC | $15.87 | 2020 | |
| Akorn Operating Company LLC | $14.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Antonello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.